LRCX Trails Peers Out of Earnings, Street Targets Sit 40% Above the Stock

Lam Research closed Friday at $239.11, down 6% on the day and 26% below where it stood a month ago, yet short interest has climbed 13% over the past week to 2.3% of the free float, the sharpest weekly rise in the ORTEX series for this name in recent months, running 1.7 standard deviations above the typical weekly move.

That short interest increase is notable for its speed, not its size. At 2.3% of the float, the absolute level remains low. The borrow market confirms there is no squeeze dynamic in play: availability is effectively unlimited, with over 750 million shares available to lend, and the cost to borrow has risen 72% on the week but from a negligible base, reaching just 0.46%. What the weekly surge in short shares does suggest is that some traders are adding directional bets against the stock specifically, not just riding the broader sector lower. Options positioning has moved in the opposite direction: the put/call ratio has fallen to 1.04, well below its 20-day average of 1.10, sitting near the lower end of the past year's range. That divergence between rising short interest and lighter put buying is the most unusual feature of the current setup.

The peer comparison sharpens the picture. Over the past week, AMAT gained 12.3%, KLAC rose 13.3%, and COHU added 15.4%. LRCX gained only 3.9% over the same stretch, a significant underperformance against the semiconductor equipment cohort median of roughly 11%. That relative lag follows a prior week in which LRCX tracked the group almost exactly lower, as documented in preceding ORTEX notes. The pattern has now shifted: the group has bounced, and LRCX has not kept pace.

Every analyst who moved on the name in late October cut their price target, but none dropped their rating. UBS trimmed to $400, Citigroup to $435, Morgan Stanley to $339, and Needham made the sharpest cut, pulling its target from $390 to $290, still 21% above Friday's close. Even the lowest target on the Street stands well above $239. The bull case rests on LRCX's dominant position in etch and number-two slot in CVD, record gross margin of 52.4% last quarter, and management's view that wafer fab equipment spending could exceed $200 billion in calendar 2027. The bear case centres on near-term China weakness, supply-chain constraints flagged for the current quarter, and guidance that implies only modest sequential growth. The stock trading 40% below the consensus price target is either a signal the Street has not yet fully marked down its estimates, or an unusual dislocation between analyst conviction and market pricing.

The November 3 print is therefore less a test of whether Lam can grow and more a test of whether the China headwind is as contained as management suggested last quarter, and whether current-quarter Systems revenue holds up against the supply-chain constraints that were cited as the binding constraint on guidance.